[Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].Fortschr Med. 1991 Nov 30; 109(34):707-10.FM
Abstract
The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated.
METHOD
open, non-controlled surveillance study conducted at 744 centers.
PATIENTS
3,076 patients suffering from bronchitis.
MEDICATION
600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose.
END POINTS
evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance.
RESULTS
impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%).
CONCLUSIONS
treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.
MeSH
Pub Type(s)
English Abstract
Journal Article
Language
ger
PubMed ID
1765342
Citation
Gerards, H H., and U Vits. "[Therapy of Bronchitis. Successful Single-dosage Treatment With N-acetylcysteine, Results of an Administration Surveillance Study in 3,076 Patients]." Fortschritte Der Medizin, vol. 109, no. 34, 1991, pp. 707-10.
Gerards HH, Vits U. [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. Fortschr Med. 1991;109(34):707-10.
Gerards, H. H., & Vits, U. (1991). [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. Fortschritte Der Medizin, 109(34), 707-10.
Gerards HH, Vits U. [Therapy of Bronchitis. Successful Single-dosage Treatment With N-acetylcysteine, Results of an Administration Surveillance Study in 3,076 Patients]. Fortschr Med. 1991 Nov 30;109(34):707-10. PubMed PMID: 1765342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].
AU - Gerards,H H,
AU - Vits,U,
PY - 1991/11/30/pubmed
PY - 1991/11/30/medline
PY - 1991/11/30/entrez
SP - 707
EP - 10
JF - Fortschritte der Medizin
JO - Fortschr Med
VL - 109
IS - 34
N2 - UNLABELLED: The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. METHOD: open, non-controlled surveillance study conducted at 744 centers. PATIENTS: 3,076 patients suffering from bronchitis. MEDICATION: 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. END POINTS: evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance. RESULTS: impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%). CONCLUSIONS: treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.
SN - 0015-8178
UR - https://www.unboundmedicine.com/medline/citation/1765342/
L2 - https://medlineplus.gov/acutebronchitis.html
DB - PRIME
DP - Unbound Medicine
ER -